ATOSSA THERAPEUTICS INC (ATOS) Stock Overview
NASDAQ:ATOS - US04962H5063 - Common Stock
ATOS Key Statistics, Chart & Performance
The current stock price of ATOS is 0.7775 USD. In the past month the price decreased by -7.43%. In the past year, price decreased by -45.25%.
ATOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.04B | ||
| AMGN | AMGEN INC | 13.47 | 158.13B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 62.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.56B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.35 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About ATOS
Company Profile
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 13 full-time employees. The company went IPO on 2012-11-08. The company is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. The company is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. The company has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Company Info
ATOSSA THERAPEUTICS INC
10202 5Th Avenue Ne, Suite 200
Seattle WASHINGTON 98104 US
CEO: Steven C. Quay
Employees: 15
Phone: 12065880256
ATOSSA THERAPEUTICS INC / ATOS FAQ
What is the stock price of ATOSSA THERAPEUTICS INC today?
The current stock price of ATOS is 0.7775 USD. The price increased by 4.5% in the last trading session.
What is the ticker symbol for ATOSSA THERAPEUTICS INC stock?
The exchange symbol of ATOSSA THERAPEUTICS INC is ATOS and it is listed on the Nasdaq exchange.
On which exchange is ATOS stock listed?
ATOS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ATOSSA THERAPEUTICS INC stock?
10 analysts have analysed ATOS and the average price target is 5.74 USD. This implies a price increase of 637.94% is expected in the next year compared to the current price of 0.7775. Check the ATOSSA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATOSSA THERAPEUTICS INC worth?
ATOSSA THERAPEUTICS INC (ATOS) has a market capitalization of 100.43M USD. This makes ATOS a Micro Cap stock.
How many employees does ATOSSA THERAPEUTICS INC have?
ATOSSA THERAPEUTICS INC (ATOS) currently has 15 employees.
What are the support and resistance levels for ATOSSA THERAPEUTICS INC (ATOS) stock?
ATOSSA THERAPEUTICS INC (ATOS) has a support level at 0.77 and a resistance level at 0.79. Check the full technical report for a detailed analysis of ATOS support and resistance levels.
Should I buy ATOSSA THERAPEUTICS INC (ATOS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATOS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATOS, evaluating the profitability, health, valuation and growth aspects
- ATOSSA THERAPEUTICS INC (ATOS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATOSSA THERAPEUTICS INC (ATOS) Sales and EPS estimates to see what analysts future expectations are.
- ATOSSA THERAPEUTICS INC (ATOS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATOSSA THERAPEUTICS INC (ATOS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATOSSA THERAPEUTICS INC (ATOS) Stock Chart to make your own analysis
- ATOSSA THERAPEUTICS INC (ATOS) Latest news and press-releases to stay up to date.
Does ATOSSA THERAPEUTICS INC (ATOS) stock pay dividends?
ATOS does not pay a dividend.
When does ATOSSA THERAPEUTICS INC (ATOS) report earnings?
ATOSSA THERAPEUTICS INC (ATOS) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of ATOSSA THERAPEUTICS INC (ATOS)?
ATOSSA THERAPEUTICS INC (ATOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.23).
What is the Short Interest ratio of ATOSSA THERAPEUTICS INC (ATOS) stock?
The outstanding short interest for ATOSSA THERAPEUTICS INC (ATOS) is 2.95% of its float. Check the ownership tab for more information on the ATOS short interest.
ATOS Technical Analysis
ATOS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ATOS. While ATOS has a great health rating, there are worries on its profitability.
ATOS Financial Highlights
Over the last trailing twelve months ATOS reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 4.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.51% | ||
| ROE | -49.78% | ||
| Debt/Equity | 0 |
ATOS Forecast & Estimates
10 analysts have analysed ATOS and the average price target is 5.74 USD. This implies a price increase of 637.94% is expected in the next year compared to the current price of 0.7775.